Published in J Thromb Haemost on November 23, 2009
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost (2012) 1.35
The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis (2014) 0.90
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics (2014) 0.83
Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial. Expert Rev Hematol (2011) 0.83
Clinical use of factor VIII and factor IX concentrates. Blood Transfus (2013) 0.80
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia (2013) 0.78
Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol (2012) 0.78
Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Res Protoc (2016) 0.77
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Des Devel Ther (2014) 0.77
Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence (2014) 0.75
Target of prophylaxis in severe haemophilia: more than factor levels. Blood Transfus (2012) 0.75
The History of Clotting Factor Concentrates Pharmacokinetics. J Clin Med (2017) 0.75
Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics. J Blood Med (2015) 0.75
Aspects of prophylactic treatment of hemophilia. Thromb J (2016) 0.75
[Treatment of haemophilia in Austria]. Wien Klin Wochenschr (2015) 0.75
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Are randomized clinical trials the only truth? Not always. J Thromb Haemost (2006) 3.34
Primary structural: analysis of the transplantation antigens of the murine H-2 major histocompatibility complex. Annu Rev Biochem (1981) 2.93
stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58
The dissociation of discriminative and conditioned reinforcing functions of stimuli with changes in deprivation. J Exp Anal Behav (1968) 2.24
One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. J Intern Med (2007) 2.19
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 2.05
Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.88
European principles of haemophilia care. Haemophilia (2008) 1.84
Molecular characterization of a carbon transporter in plastids from heterotrophic tissues: the glucose 6-phosphate/phosphate antiporter. Plant Cell (1998) 1.82
Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. Br J Surg (2010) 1.71
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet (2002) 1.56
Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol (1987) 1.53
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost (2008) 1.48
Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology (1993) 1.47
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia (2005) 1.46
Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. Am J Hematol (1995) 1.45
Comparison of standard endoscopic submucosal dissection (ESD) versus an optimized ESD technique for the colon: an animal study. Endoscopy (2009) 1.44
A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis. Surg Endosc (2006) 1.42
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia (2010) 1.41
Cerebral vasoconstriction by indomethacin in intracranial hypertension. An experimental investigation in pigs. Anesthesiology (1995) 1.40
Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia (2007) 1.40
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood (1996) 1.39
[Argon plasma surgery (APC) in the upper aerodigestive tract. Initial results]. HNO (1998) 1.39
A case-control study on the psychological aspects and coping in haemophilic patients. Haemophilia (2004) 1.39
Morphine antagonises action of prostaglandin in neuroblastoma and neuroblastoma times glioma hybrid cells. Nature (1975) 1.38
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost (2012) 1.35
Construction and characterization of a Plasmodium vivax genomic library in yeast artificial chromosomes. Genomics (1997) 1.34
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Social science. Promoting transparency in social science research. Science (2014) 1.33
Sequence analysis and protein import studies of an outer chloroplast envelope polypeptide. Proc Natl Acad Sci U S A (1990) 1.33
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost (2008) 1.29
Localization of the papain cleavage site of H-2 glycoproteins. Proc Natl Acad Sci U S A (1976) 1.28
Expression of the functional mature chloroplast triose phosphate translocator in yeast internal membranes and purification of the histidine-tagged protein by a single metal-affinity chromatography step. Proc Natl Acad Sci U S A (1993) 1.28
Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells. J Immunol (2000) 1.27
High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin (2011) 1.26
The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia (2004) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality (1995) 1.25
Seven-day activity and self-report compared to a direct measure of physical activity. Am J Epidemiol (1984) 1.21
Transforaminal arthroscopic decompression of lateral recess stenosis. J Neurosurg (1996) 1.20
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia (2004) 1.19
Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion (2001) 1.18
National survey of neonatal transfusion practices: I. Red blood cell therapy. Pediatrics (1993) 1.17
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia (2009) 1.16
The 'prespore-like cells' of Dictyostelium have ceased to express a prespore gene: analysis using short-lived beta-galactosidases as reporters. Development (1994) 1.15
Expression of the triose phosphate translocator gene from potato is light dependent and restricted to green tissues. Mol Gen Genet (1993) 1.14
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia (2012) 1.13
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. Acta Anaesthesiol Scand (2001) 1.12
Lifetime occupation, education, smoking, and risk of ALS. Neurology (2007) 1.12
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol (1998) 1.12
Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood (1995) 1.12
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost (2008) 1.11
Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol (1991) 1.11
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia (2004) 1.10
Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia (2003) 1.10
[Subependymal cell proliferation and tumor disposition in brachycephalic dog breeds]. Acta Neuropathol (1967) 1.09
Arsenic exposure, smoking, and respiratory cancer in copper smelter workers. Arch Environ Health (1983) 1.09
Thoracoscopic sympathectomy for upper limb hyperhidrosis: looking for the right operation. Ann Thorac Surg (1997) 1.09
Diagnostics and therapy of lymphoceles after kidney transplantation. Transplant Proc (2006) 1.08
Current status of the Plasmodium falciparum genome project. Mol Biochem Parasitol (1996) 1.08
B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun (2001) 1.08
Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia (2011) 1.07
Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia (2011) 1.07
Parasitism and chromosome dynamics in protozoan parasites: is there a connection? Mol Biochem Parasitol (1995) 1.07
High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (2000) 1.06
Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. Carcinogenesis (2001) 1.06
Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia (2011) 1.05
Clinical pharmacology of thalidomide. Eur J Clin Pharmacol (2001) 1.05
Jaw fractures in the County of Kopparberg and Stockholm 1979-1988. A retrospective comparative study of frequency and cause with special reference to assault. Swed Dent J (1991) 1.05
Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence of the amino-terminal one hundred and seventy-three residues of the H-2Kb glycoprotein. Biochemistry (1980) 1.05
Eating soya improves human memory. Psychopharmacology (Berl) (2001) 1.04
Continuous in vitro propagation and differentiation of cultures of the intramolluscan stages of the human parasite Schistosoma mansoni. Proc Natl Acad Sci U S A (1999) 1.04
Further structural analysis of the murine H-2Kb glycoprotein using radiochemical methodology. Mol Immunol (1979) 1.03
Application of quantitative light-induced fluorescence to monitor incipient lesions in caries-active children. A comparative study of remineralisation by fluoride varnish and professional cleaning. Eur J Oral Sci (2001) 1.02
Bee venom neurotoxin (apamin): iodine labeling and characterization of binding sites. Eur J Biochem (1979) 1.02
A study on HIV and hepatitis C virus among commercial sex workers in Tallinn. Sex Transm Infect (2008) 1.02
EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res (2011) 1.02
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood (1996) 1.01
Primary structure of murine major histocompatibility complex alloantigens: isolation, biochemical characterization, and preliminary alignment of CNBr fragments from the H-2Ib glycoprotein. Proc Natl Acad Sci U S A (1978) 1.01